BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23582562)

  • 1. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review.
    Souza SJ; Luzia LA; Santos SS; Rondó PH
    Rev Assoc Med Bras (1992); 2013; 59(2):186-98. PubMed ID: 23582562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
    Sension M; Deckx H
    AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W; Luaengniyomkul A; Manosuthi W
    J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.
    Liu E; Armstrong C; Spiegelman D; Chalamilla G; Njelekela M; Hawkins C; Hertzmark E; Li N; Aris E; Muhihi A; Semu H; Fawzi W
    Clin Infect Dis; 2013 Jun; 56(12):1820-8. PubMed ID: 23449270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI.
    Liu S; Wei B; Liang W; Chen T; Deng L; Zhao M; Wan J
    Front Public Health; 2023; 11():1161503. PubMed ID: 37181701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching strategies to improve lipid profile and morphologic changes.
    Barragan P; Fisac C; Podzamczer D
    AIDS Rev; 2006; 8(4):191-203. PubMed ID: 17219734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy.
    Bergersen BM
    Drugs; 2006; 66(15):1971-87. PubMed ID: 17100407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma lipid profile in pregnant women with HIV receiving nevirapine.
    Floridia M; Tamburrini E; Anzidei G; Tibaldi C; Guaraldi G; Guerra B; Meloni AM; Vimercati A; Molinari A; Pinnetti C; Dalzero S; Ravizza M;
    AIDS Patient Care STDS; 2009 Mar; 23(3):147-52. PubMed ID: 19866532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
    Egaña-Gorroño L; Martínez E; Cormand B; Escribà T; Gatell J; Arnedo M
    AIDS; 2013 Feb; 27(4):529-38. PubMed ID: 23262498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid metabolism in treated HIV Infection.
    Dubé MP; Cadden JJ
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
    Bwakura-Dangarembizi M; Musiime V; Szubert AJ; Prendergast AJ; Gomo ZA; Thomason MJ; Musarurwa C; Mugyenyi P; Nahirya P; Kekitiinwa A; Gibb DM; Walker AS; Nathoo K;
    Pediatr Infect Dis J; 2015 Feb; 34(2):e23-31. PubMed ID: 25068287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
    Nolan D
    Drug Saf; 2005; 28(12):1069-74. PubMed ID: 16329710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
    Fontas E; van Leth F; Sabin CA; Friis-Møller N; Rickenbach M; d'Arminio Monforte A; Kirk O; Dupon M; Morfeldt L; Mateu S; Petoumenos K; El-Sadr W; de Wit S; Lundgren JD; Pradier C; Reiss P;
    J Infect Dis; 2004 Mar; 189(6):1056-74. PubMed ID: 14999610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study.
    Kamara DA; Smith C; Ryom L; Reiss P; Rickenbach M; Phillips A; Mocroft A; De Wit S; Law M; Monforte AD; Dabis F; Pradier C; Lundgren JD; Sabin C
    Antivir Ther; 2016; 21(6):495-506. PubMed ID: 27114439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
    Rokx C; Verbon A; Rijnders BJ
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014)].
    ;
    Enferm Infecc Microbiol Clin; 2014; 32(7):446.e1-42. PubMed ID: 24953253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.